The Group A compound piperlongumine (PIP) has been reported to selectively kill cancer cells based on cancer-specific features and this compound was previously screened using a p53-responsive reporter assay in U2OS osteosarcoma cells [38]. This evidence concerns the gene TP53 and osteosarcoma.